Public affairs shop Morgan Allen Moore has won a slice of
pharmaceutical company Abbot Laboratories' PA and media relations
With fees thought to be in six figures, the agency will work on
Respiratory Syncytial Virus (RSV) - a condition that affects 95 to 100
per cent of babies in infancy.
A MAM spokesman said the agency had not been forced to pitch
competitively, but had been through a series of meetings with the client
in recent months.
Three other agencies were involved in this process.
Abbot senior business unit manager Hugh Griffith said: 'We decided to
use a public affairs agency to reach policy makers.'
The agency's brief will have a particular focus on Wales, where there is
a higher incidence of RSV. The agency will lobby government and health
organisations to raise the profile of the condition and its treatments -
including Abbot brand Synagis.
Agency MD Steve Morgan said: 'Having won its second term, the Government
is expanding its relationship with the healthcare sector, presenting
more opportunities for meaningful dialogue and debate.'